Our lead product for severe pneumonia, plasma gelsolin, has application for COVID19.

Share on facebook
Share on twitter
Share on linkedin

August, 2019: BioAegis Therapeutics Announces Publication in the Journal of Infectious Diseases: “Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Penicillin-Sensitive and Resistant Pneumococcal Pneumonia”

MORRISTOWN, NJ, (August 22, 2019) BioAegis Therapeutics, Inc., a clinical stage company developing technology to control inflammation while protecting immune function and vital organs in diseases driven by inflammation and infection, announces publication of research results in the Journal of Infectious Diseases demonstrating that recombinant human plasma gelsolin therapy dramatically improves survival in a multidrug-resistant pneumonia animal model.   Furthermore, it works synergistically with previously ineffective antibiotics, making them work again.

Read the full press release here:  JID Publication Final 8-22-2019